Immix Biopharma, Inc.: Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial ...
Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in developme ...
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December ...